Tag Archives: Wnt

Leap’s Two Early-Stage Immuno-Oncology Antibodies

Leap Therapeutics, an immuno-oncology company, recently reversed merge with Macrocure to become a publicly traded company, and received an investment of $10MM from current investors in order to advance two antibodies –  DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein on cancer cells, and TRX518, a humanized GITR agonist that augments T-cell responses against tumors. Continue reading →

Biomarkers for Wnt activation Predict For HER-2(-) Breast Cancer and NSCLC Response to Vantictumab

OncoMed is developing several compounds that target Wnt and Notch pathways, which are important in cancer and cancer stem cell maintenance, survival, and proliferation. Biomarkers for response of Her-2-negative breast cancer and non-small cell lung cancer (NSCLC) following treatment with Vantictumab, anti-Wnt monoclonal antibody, have been developed. Continue reading →

Targeting Cancer Stem Cells – OncoMed’s R-SPONDIN LGR Antibody for Colorectal Cancer

OncoMed initiated a Phase I/II trial of its anti-RSPO3 antibody (OMP-131R10) in patients with relapsed colorectal cancer. Patients will also be receiving FOLFIRI (5-FU, irinotecan, leucovorin). Continue reading →

OncoMed’s Wnt-targeted experimental cancer drugs and bone-related adverse events

OncoMed is a biotech company that is developing therapies directed at the Wnt and Notch signaling pathways.  Clinical studies with two products directed at the Wnt pathway (Vantictumab – anti-Fzd-7, and Fzd-8 Fc) have been halted by the company while it explores findings of bone toxicity. Continue reading →